Massoth C, Küllmar M, Enders D, et al. - This single-center, prospective, observational study was conducted to determine if biomarkers, including C-C motif chemokine ligand 14 (CCL14), can predict persistent acute kidney injury (AKI) as well as major adverse kidney events (MAKE) after cardiac surgery. Persistent severe AKI (KDIGO3) lasting for ≥ 72h was the primary endpoint. An area under the curve (AUC) of 0.930 was afforded by CCL14 as the most predictive biomarker for the primary endpoint. A significantly higher AUC was offered by CCL14 vs AUCs for the other biomarkers assessed. Overall, persistent AKI was predicted by increased CCL14 levels in cardiac surgery patients experiencing moderate or severe AKI. With the help of this new biomarker, stratification of patients destined to undergo renal replacement therapy as well as detection of patients for whom novel therapeutic approaches to AKI may be beneficial, may be accomplished.